Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus.

Dapagliflozin and empagliflozin showed no significant difference of real-world clinical cardiovascular outcomes in patients with DM over a 3-year period. Further large randomized clinical trials will be warranted for better evaluation.